Arcus Biosciences (RCUS) Cash from Operations (2017 - 2025)
Historic Cash from Operations for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$97.0 million.
- Arcus Biosciences' Cash from Operations fell 47307.69% to -$97.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$462.0 million, marking a year-over-year decrease of 19240.51%. This contributed to the annual value of -$170.0 million for FY2024, which is 4444.44% up from last year.
- Per Arcus Biosciences' latest filing, its Cash from Operations stood at -$97.0 million for Q3 2025, which was down 47307.69% from -$133.0 million recorded in Q2 2025.
- In the past 5 years, Arcus Biosciences' Cash from Operations ranged from a high of $654.0 million in Q1 2022 and a low of -$133.0 million during Q2 2025
- Its 5-year average for Cash from Operations is -$34.5 million, with a median of -$70.0 million in 2022.
- Per our database at Business Quant, Arcus Biosciences' Cash from Operations soared by 108618.73% in 2022 and then plummeted by 650000.0% in 2025.
- Quarter analysis of 5 years shows Arcus Biosciences' Cash from Operations stood at -$61.9 million in 2021, then decreased by 13.03% to -$70.0 million in 2022, then decreased by 25.71% to -$88.0 million in 2023, then fell by 13.64% to -$100.0 million in 2024, then rose by 3.0% to -$97.0 million in 2025.
- Its Cash from Operations stands at -$97.0 million for Q3 2025, versus -$133.0 million for Q2 2025 and -$132.0 million for Q1 2025.